Personalized medicine in oncology: A personal view with myths and facts

Current Clinical Pharmacology

Volumn 5, Issue 3, 2010, Pages 141-147

  Beijnen, Jos H ^a,b   Schellens, Jan H M ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antibodies; Resistance; Side effects; Small molecules; Targeted therapy

Indexed keywords

BUSULFAN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; MERCAPTOPURINE; METHOTREXATE; OLAPARIB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PLX 4032; RITUXIMAB; SORAFENIB; SUNITINIB; TAMOXIFEN; TAMOXIFEN CITRATE; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; HUMAN; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PATIENT CARE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 78649351681     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410791498789     Document Type: Article

References (47)

1. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and the body surface area. Eur J Cancer 2002; 38: 1677-84
2. Cuzick J, Powles T, Veronesi U, et al. Overview of the main out-comes in breast-cancer prevention trials. Lancet 2003; 361: 296-300
3. Fischgräbe J, Wlfing P. Targeted therapies in breast cancer: estabished drugs and recent developments. Curr Clin Pharmacol 2008;3: 85-98
4. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010; 67: 257-74
5. Ortega J, Vigil CE, Chodkiewics C. Current progress in targeted therapy for colorectal cancer. Cancer Control 2010; 17: 7-15.
6. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502
7. Redner RL. Why doesn't imatinib cure chronic myeloid leukemia? Oncologist 2010; 15(2): 182-6
8. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17
9. Palandri F, Iacobucci I, Castagnetti F, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5 year outcome. Haematologica 2008; 93: 770-4
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72
11. Meza-Junco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009; 9: 1543-51
12. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497
13. Shephard FA, Rodrigues Pereira J, Ciuleanue T, et al. Erlotinib in previously treated non-small lung cancer. N Engl J Med 2005; 353: 123-32
14. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44
15. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-67
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor anderlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39
17. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-37
18. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-42
19. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-18
20. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34
21. Allegra CJ, Jessup JM, Somerfield MR, et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-6
22. Fakih MM. KRAS mutation screening in colorectal cancer: From paper to practice. Clin Colorectal Cancer 2010; 9: 22-30
23. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-12
24. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10: 1179-87
25. Apperley JF. Mechanisms of resistance to imatinib in chronic myeloid leukemia. Part I. Lancet Oncol 2007; 8: 1018-29
26. Apperley JF. Management of resistance to imatinib in chronic myeloid leukemia. Part II. Lancet Oncol 2007; 8: 1116-28
27. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401
28. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med 2006; 354: 2531-41
29. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-44
30. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500
31. Rodon J, Perez J, Kurzrock R. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist 2010; 15: 37-50
32. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996; 24: 153-72
33. Booth BP, Rahman A, Dagher R, et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 2007; 47: 101-11
34. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy: efficacy, safety, and pharmacologic basis of an intermittent single high-dose schedule. Cancer 1974; 33: 19-27
35. Joerger M, Huitema ADR, Huizing MT, et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 2007; 64: 622-33
36. Liliemark J, Peterson C. Purine analogs and antifolates. In: Schellens JHM, McLeod HL, Newell DR Eds. Cancer Clinical Pharmacology. Oxoford University Press. 2005; pp. 63-83
37. Fujita K-I, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 2010; 5 [Epub ahead of print]
38. Bosch TM. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol 2008; 448: 63-76
39. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56
40. Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garcia MJ. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 2006; 45: 1227-38
41. Meza-Junco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009; 9: 1543-51
42. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010: 28: 1138-44.
43. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42
44. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17
45. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43
46. Garber K. Cancer research. Melanoma drug vindicates targeted approach. Science 2009; 326: 1619
47. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BCRA mutation carriers. N Engl J Med 2009; 361: 123-34.